Androgen Independent Prostate Cancer News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
·Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with PTEN loss tumoursBasel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCR...
Source: Roche Media News - June 19, 2020 Category: Pharmaceuticals Source Type: news
Oncotarget: hPCL3S promotes proliferation and migration of androgen-independent prostate cancer cells
(Impact Journals LLC) The cover for issue 12 of Oncotarget features Figure 11, 'Global analyses of the RNA-Seq data of LNCaP empty vector and LNCaP cells overexpressing hPCL3S (Clone 12)' by Abdelfettah, et al. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 25, 2020 Category: Cancer & Oncology Source Type: news